Literature DB >> 6175407

Modulation of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2'-deoxycoformycin during therapy with 9-beta-D-arabinofuranosyladenine.

W Plunkett, R S Benjamin, M J Keating, E J Freireich.   

Abstract

The effect of the adenosine deaminase inhibitor, 2'-deoxycoformycin, on cellular nucleotides during therapy with continuous infusion of 9-beta-D-arabinofuranosyladenine (ara-A) has been investigated. In three courses of treatment using increasing doses, the active 5'-triphosphate of ara-A, 9-beta-D-arabinofuranosyladenine 5'-triphosphate (ara-ATP) accumulated in leukemic cells and erythrocytes from a patient treated for acute lymphocytic leukemia in proportion to the dose of ara-A. The cellular ara-ATP concentration increased more than 5-fold after the injection of a single, nontoxic, but pharmacologically active dose of 2'-deoxycoformycin 24 hr after initiation of ara-A infusion. However, this response was associated with a concomitant increase in the cellular deoxyadenosine triphosphate concentrations to levels equal to or greater than those of ara-ATP throughout the three treatment courses studied. Consistent with previous results using cell-free systems, it was demonstrated that a competitive relationship exists between deoxyadenosine triphosphate and ara-ATP for the inhibition of DNA synthesis in cultured human lymphoblastoid cells and that the ratio of the cellular concentrations of these nucleotides could predict the extent of inhibition of DNA synthesis. Application of this rationale to the nucleotides in the leukemic cells of the patient suggested that administration of 2'-deoxycoformycin may create a cellular biochemical milieu that could be antagonistic to the inhibition of DNA synthesis by ara-ATP.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6175407

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.

Authors:  S A Johnson
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

2.  Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia.

Authors:  S A Johnson; D Catovsky; J A Child; A C Newland; D W Milligan; R Janmohamed
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

Review 3.  Comparative pharmacokinetics of antiviral nucleoside analogues.

Authors:  G D Morse; M J Shelton; A M O'Donnell
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

4.  9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.

Authors:  L Danhauser; W Plunkett; M Keating; F Cabanillas
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 5.  Evolution of the arabinosides and the pharmacology of fludarabine.

Authors:  W Plunkett; V Gandhi
Journal:  Drugs       Date:  1994       Impact factor: 9.546

6.  Potentiation of growth-inhibitory activity of 9-beta-D-arabinofuranosyladenine by 2'-deoxycoformycin in human cultured cell lines derived from leukemias and lymphomas.

Authors:  Y Kuroki; M Shimoyama; S Inaba; M Hirose
Journal:  Jpn J Cancer Res       Date:  1989-05

Review 7.  Marine Natural Products in Clinical Use.

Authors:  Neshatul Haque; Sana Parveen; Tingting Tang; Jiaen Wei; Zunnan Huang
Journal:  Mar Drugs       Date:  2022-08-18       Impact factor: 6.085

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.